MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee
May 3, 2019
9:00 A.M.
Conference Center Room “A”
Indiana State Government Center South

1. Call to Order–Chair
2. Opening Comments–OMPP
3. Approval of Memoranda, Meeting of November 2, 2018 and February 1, 2019
4. Election of Committee Officers – CY2019
5. Preferred Drug List: Therapeutic Class Re-Review
   a) Respiratory
      i. Antihistamine-Decongestant Combinations/2\textsuperscript{nd} Generation Antihistamines
      ii. Antiviral Monoclonal Antibodies
      iii. Beta Adrenergics and Corticosteroids
      iv. Beta Agonists
      v. Bronchodilator Agents – Beta Adrenergic and Anticholinergic Combinations
      vi. Leukotriene Receptor Antagonists
      vii. Monoclonal Antibodies for the Treatment of Respiratory Conditions
      viii. Nasal Antihistamines/Nasal Anti-Inflammatory Steroids
ix. Oral Inhaled Glucocorticoids
x. Phosphodiesterase-4 Inhibitors
xi. Pulmonary Antihypertensives

b) Anti-Infectives
   i. Antivirals – Anti-Herpetic Agents
   ii. Antivirals – Influenza Agents
   iii. Cephalosporins – 3rd Generation
   iv. Fluoroquinolones
   v. Hepatitis C Agents
   vi. Macrolides
   vii. Ophthalmic Antibiotics
   viii. Ophthalmic Antibiotics/Corticosteroid Combinations
   ix. Oral Non-Systemic Antifungals
   x. Otic Antibiotics
   xi. Systemic Antifungals
   xii. Topical Antifungals
   xiii. Topical Antivirals
   xiv. Topical Antivirals and Anti-Inflammatory Steroid Combinations
   xv. Vaginal Antimicrobials

c) Cardiovascular
   i. Angiotensin-Converting Enzyme (ACE) Inhibitors
   ii. ACE Inhibitor Combinations
   iii. Alpha Adrenergic Blockers
   iv. Angiotensin II Receptor Antagonists (ARBs)
   v. ARB Combinations
   vi. Beta Adrenergic Blockers
   vii. Beta Adrenergic Blockers with Diuretics
   viii. Calcium Channel Blockers (CCBs)
   ix. CCBs with HMG-CoA Reductase Inhibitors
   x. Miscellaneous Cardiac Agents

d) Lipotropics
i. Bile Acid Sequestrants
ii. Fibric Acid Derivatives
iii. HMG-CoA Reductase Inhibitors
iv. Lipotropics
e) Antimigraine Agents
f) Electrolyte Depleters
g) Multiple Sclerosis Agents
h) CNS and Others
i. Agents for the Treatment of Opiate Addiction
   ii. Antiemetic/Antivertigo Agents
iii. Antiseizure Agents
iv. Gastroprotective NSAIDs
   v. Narcotic Antitussive/1st Generation Antihistamine Combinations
   vi. Narcotics
   vii. Skeletal Muscle Relaxants
   viii. Smoking Deterrent Agents
i) Dermatologic Agents
   i. Acne Agents
   ii. Antipsoriatic Agents
j) Endocrine
   i. Anaphylaxis Agents
   ii. Antidiabetic Agents, Oral
   iii. Bone Formation Stimulating Agents
   iv. Growth Hormones
   v. Injectable Hypoglycemics, Insulin
   vi. Injectable Hypoglycemics, Non-Insulin and Combination
   vii. Bone Resorption Inhibitors
   viii. Testosterones
k) Estrogen and Related Agents
   i. Estrogen and Related Agents
l) Gastrointestinal Agents
i. Antiulcer Agents
ii. *H. Pylori* Agents
iii. H2 Receptor Antagonists
iv. Laxatives and Cathartics
  v. Pancreatic Enzymes
vi. Proton Pump Inhibitors
vii. Ulcerative Colitis Agents

m) Genitourinary Agents
   i. Benign Prostatic Hypertrophy Agents
   ii. Urinary Tract Antispasmodic/Anti-Incontinence Agents

n) Hematologic Agents
   i. Direct Factor Xa Inhibitors
   ii. Direct Thrombin Inhibitors
   iii. Hematinics
   iv. Heparin and Related Products
   v. Leukocyte (WBC) Stimulants
   vi. Platelet Aggregation Inhibitors

o) Targeted Immunomodulators

p) Topical Agents
   i. Miotics -Intraocular Pressure Reducers
   ii. Ophthalmic Antihistamines
   iii. Ophthalmic Anti-Inflammatory Agents
   iv. Ophthalmic Anti-Inflammatory Agents, Immunomodulator-Type
   v. Ophthalmic Mast Cell Stabilizers
   vi. Otic Preparations
   vii. Topical Anti-Inflammatory Agents-NSAIDs
   viii. Topical Antiparasitics
   ix. Topical Immunomodulators
   x. Topical Post Herpetic Neuralgia Agents
   xi. Wound Care Products

6. IHCP Opioid Data Update and Review
7. New Business
8. Public Comment
9. Other Business
10. Adjourn